<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803010</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15372</org_study_id>
    <secondary_id>IRB 106591</secondary_id>
    <nct_id>NCT00803010</nct_id>
  </id_info>
  <brief_title>Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation</brief_title>
  <official_title>Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to compare the effectiveness of Tacrolimus and Rapamycin to
      Tacrolimus and Methotrexate in the prevention of severe graft-versus-host-disease.
      Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell
      transplants (HCT). An allogeneic hematopoietic cell transplant is a transplant using bone
      marrow and blood cells that come from someone other than the patient (a donor).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All drugs used in this study have been used in the prevention of graft-versus-host-disease
      after allogeneic hematopoietic cell transplant. Tacrolimus and Methotrexate used in
      combination are currently used as standard of care in the prevention of
      graft-versus-host-disease after allogeneic hematopoietic cell transplant. Tacrolimus and
      Rapamycin is a newer combination we are testing to see if it would be better than Tacrolimus
      and Methotrexate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant</measure>
    <time_frame>100 Days Post Transplant</time_frame>
    <description>Incidence of acute graft versus host disease grades 2-3 according to the Common Toxicity Criteria (CTC) version 3.
Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell transplants (HCT). Clinical evidence of acute GVHD was recorded per standard grading scheme.
Acute GVHD classified as the following:
classic acute GVHD - onset within 100 days after transplant
persistent - acute GVHD with onset prior to day 100 and without resolution beyond day 100
recurrent - acute GVHD recurrent after prior episode of acute GVHD
late acute GVHD - syndrome consistent with acute GVHD, without features of chronic GVHD, with onset occurring beyond 100 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Increased Absolute Numbers of Regulatory T Cells (Treg)</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Absolute numbers of Treg at designated time points according to study arm. MTX = methotrexate/tacrolimus-treated patients; SIR = sirolimus/tacrolimus-treated patients; Treg absolute number units = number of cells/microL. A two-sided Wilcoxon's rank-sum test was employed to test differences in percent Treg (% Treg/total CD4+ cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Year Post Transplant Overall Survival (OS) Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as time from transplantation (day 0 as day of stem cell infusion per standard nomenclature) to death from any cause .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Acute Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Tacrolimus / Rapamycin (TAC/RAPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus: beginning 3 days before transplant and given for at least 50 days.
Rapamycin: given the day before transplant and continued daily for at least one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus / Methotrexate (TAC/MTX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus: beginning 3 days before transplant and given for at least 50 days.
Methotrexate: given on days 1, 3, 6 and 11, after transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus (TAC)</intervention_name>
    <description>Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.</description>
    <arm_group_label>Tacrolimus / Rapamycin (TAC/RAPA)</arm_group_label>
    <arm_group_label>Tacrolimus / Methotrexate (TAC/MTX)</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
    <arm_group_label>Tacrolimus / Methotrexate (TAC/MTX)</arm_group_label>
    <other_name>Trexall</other_name>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (RAPA)</intervention_name>
    <description>Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
    <arm_group_label>Tacrolimus / Rapamycin (TAC/RAPA)</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 16 and ≤ 70

          -  Signed informed consent

          -  Adequate vital organ function

          -  No active infection, or asymptomatic infection well controlled by antibiotic HIV
             negative by ELISA or RT-PCR [if ELISA is positive and RT-PCR is negative, the ELISA is
             considered false positive]

          -  Hepatitis B and C negative by serology or RT-PCR

          -  Performance status: Karnofsky Performance Status Score ≥ 60%.

        Exclusion Criteria:

          -  Those with any Sorror's co-morbidity factors with score &gt; 3

          -  2 or more Sorror's factors with composite score of ≥ 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Anasetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>HLeeMoffittCancerCenter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H.Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/</url>
    <description>H.Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>December 10, 2013</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>July 10, 2015</last_update_submitted>
  <last_update_submitted_qc>July 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Graft Versus Host Disease (aGVHD)</keyword>
  <keyword>GVHD</keyword>
  <keyword>graft-versus-host disease</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>sirolimus</keyword>
  <keyword>methotrexate</keyword>
  <keyword>combination therapy</keyword>
  <keyword>GVHD prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited between 09/10/2008 through 05/13/2011 from the Blood and Marrow Transplant Program patient population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Tacrolimus / Rapamycin</title>
          <description>Tacrolimus / Rapamycin
Tacrolimus and Rapamycin (Sirolimus): Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>2 Tacrolimus / Methotrexate</title>
          <description>Tacrolimus / Methotrexate
Tacrolimus and Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on our preliminary data collected from patients receiving TAC/MTX, the acute GVHD (aGVHD) rate is estimated to be 80% at 100 days. A two-sided log-rank test will achieve 90% power at a 0.1 significance level. The result of this calculation serves as an approximation of power/sample size for the test we propose to use for the primary endpoint.</population>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus / Rapamycin</title>
          <description>Tacrolimus / Rapamycin
Tacrolimus / Rapamycin: Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus / Methotrexate</title>
          <description>Tacrolimus / Methotrexate
Tacrolimus / Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="25" upper_limit="68"/>
                    <measurement group_id="B2" value="48" lower_limit="23" upper_limit="69"/>
                    <measurement group_id="B3" value="49" lower_limit="23" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant</title>
        <description>Incidence of acute graft versus host disease grades 2-3 according to the Common Toxicity Criteria (CTC) version 3.
Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell transplants (HCT). Clinical evidence of acute GVHD was recorded per standard grading scheme.
Acute GVHD classified as the following:
classic acute GVHD - onset within 100 days after transplant
persistent – acute GVHD with onset prior to day 100 and without resolution beyond day 100
recurrent – acute GVHD recurrent after prior episode of acute GVHD
late acute GVHD – syndrome consistent with acute GVHD, without features of chronic GVHD, with onset occurring beyond 100 days</description>
        <time_frame>100 Days Post Transplant</time_frame>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tacrolimus / Rapamycin</title>
            <description>Tacrolimus / Rapamycin
Tacrolimus and Rapamycin (Sirolimus): Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>2 Tacrolimus / Methotrexate</title>
            <description>Tacrolimus / Methotrexate
Tacrolimus and Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant</title>
          <description>Incidence of acute graft versus host disease grades 2-3 according to the Common Toxicity Criteria (CTC) version 3.
Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell transplants (HCT). Clinical evidence of acute GVHD was recorded per standard grading scheme.
Acute GVHD classified as the following:
classic acute GVHD - onset within 100 days after transplant
persistent – acute GVHD with onset prior to day 100 and without resolution beyond day 100
recurrent – acute GVHD recurrent after prior episode of acute GVHD
late acute GVHD – syndrome consistent with acute GVHD, without features of chronic GVHD, with onset occurring beyond 100 days</description>
          <population>All participants who received treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="27" upper_limit="59"/>
                    <measurement group_id="O2" value="89" lower_limit="72" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Increased Absolute Numbers of Regulatory T Cells (Treg)</title>
        <description>Absolute numbers of Treg at designated time points according to study arm. MTX = methotrexate/tacrolimus-treated patients; SIR = sirolimus/tacrolimus-treated patients; Treg absolute number units = number of cells/microL. A two-sided Wilcoxon's rank-sum test was employed to test differences in percent Treg (% Treg/total CD4+ cells).</description>
        <time_frame>30 days and 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Tacrolimus / Rapamycin</title>
            <description>Tacrolimus / Rapamycin
Tacrolimus and Rapamycin (Sirolimus): Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>2 Tacrolimus / Methotrexate</title>
            <description>Tacrolimus / Methotrexate
Tacrolimus and Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Increased Absolute Numbers of Regulatory T Cells (Treg)</title>
          <description>Absolute numbers of Treg at designated time points according to study arm. MTX = methotrexate/tacrolimus-treated patients; SIR = sirolimus/tacrolimus-treated patients; Treg absolute number units = number of cells/microL. A two-sided Wilcoxon's rank-sum test was employed to test differences in percent Treg (% Treg/total CD4+ cells).</description>
          <units>Cells/MicroL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Day Measure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.27" lower_limit="12.49" upper_limit="17.89"/>
                    <measurement group_id="O2" value="9.87" lower_limit="8.59" upper_limit="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Day Measure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="10.76" upper_limit="18.1"/>
                    <measurement group_id="O2" value="9.67" lower_limit="7.48" upper_limit="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Year Post Transplant Overall Survival (OS) Rate</title>
        <description>Defined as time from transplantation (day 0 as day of stem cell infusion per standard nomenclature) to death from any cause .</description>
        <time_frame>2 years</time_frame>
        <population>All participants who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>1 Tacrolimus / Rapamycin</title>
            <description>Tacrolimus / Rapamycin
Tacrolimus and Rapamycin (Sirolimus): Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>2 Tacrolimus / Methotrexate</title>
            <description>Tacrolimus / Methotrexate
Tacrolimus and Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Year Post Transplant Overall Survival (OS) Rate</title>
          <description>Defined as time from transplantation (day 0 as day of stem cell infusion per standard nomenclature) to death from any cause .</description>
          <population>All participants who received treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="41" upper_limit="77"/>
                    <measurement group_id="O2" value="69" lower_limit="48" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus / Rapamycin</title>
          <description>Tacrolimus / Rapamycin
Tacrolimus / Rapamycin: Tacrolimus - 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Rapamycin - initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus / Methotrexate</title>
          <description>Tacrolimus / Methotrexate
Tacrolimus / Methotrexate: Tacrolimus administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Pericardial effusion</sub_title>
                <description>Cardiac General - Pericardial effusion, Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI-Lower GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Abdominal pain secondary to acute cholecystitis</sub_title>
                <description>Hepatobiliary / Pancreas, Grade 3 Abdominal pain secondary to acute cholecystitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal / Genitourinary - Obstruction, GU Bladder</sub_title>
                <description>Obstruction, GU Bladder Grade 3 Bilateral ureteral obstruction secondary to clots</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Renal / Genitourinary - Renal Failure</sub_title>
                <description>Renal Failure Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Pidala</name_or_title>
      <organization>H. Lee Moffitt Cancer Center</organization>
      <phone>813-745-4673 ext 2556</phone>
      <email>Joseph.Pidala@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

